Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc CRDL


Primary Symbol: T.CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Post by Youhillmanon Apr 21, 2021 2:55pm
184 Views
Post# 33038487

Mengel Updated Recommendation on CRDL

Mengel Updated Recommendation on CRDL

I just finished reviewing the latest edition of the 'Adventure Capitalist' by Jimmy Mengel.

Mengel just did a very comprehensive interview with Elsley covering all the bases with respect to CRDL and the work they are doing. I can't share the report / interview as it's a paid subscription, in other words not for distribution.

I can state that Mengel is very bullish on CRDL, and I will share that part of recommendation.

I'm long on CRDL as this will be a Billion Dollar Company within the next 12 months! 

Here's Mengel's recommendation.....

We're buying Cardiol Therapeutics (TSX: CRDL; OTC: CRTPF) at current prices. If you already own shares, this would be a good time to add to your position if you have the means. I expect more news to start making its way to the investment media, and a successful uplisting to the NASDAQ would be a huge boon in and of itself.

<< Previous
Bullboard Posts
Next >>